Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

38.6%

17 terminated/withdrawn out of 44 trials

Success Rate

52.8%

-33.7% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

68%

13 of 19 completed trials have results

Key Signals

4 recruiting13 with results11 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2
18(50.0%)
Phase 1
9(25.0%)
N/A
8(22.2%)
Phase 4
1(2.8%)
36Total
Phase 2(18)
Phase 1(9)
N/A(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT04990921Phase 2Recruiting

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

Role: collaborator

NCT00682032Not ApplicableRecruiting

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Role: collaborator

NCT01985087Phase 1Active Not Recruiting

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

Role: collaborator

NCT02128100Phase 2Completed

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Role: collaborator

NCT01278212Not ApplicableCompleted

Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer

Role: collaborator

NCT01871454Phase 2Recruiting

Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

Role: collaborator

NCT02143050Phase 1Withdrawn

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Role: collaborator

NCT01874860Phase 2Completed

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Role: collaborator

NCT01668849Phase 1Completed

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

Role: collaborator

NCT00263731Completed

Metabolomic Analysis of Lung Cancer

Role: collaborator

NCT02009397Phase 1Completed

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Role: collaborator

NCT01638676Phase 1Recruiting

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

Role: collaborator

NCT00553618Phase 2Active Not Recruiting

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

Role: collaborator

NCT02009384Phase 2Terminated

Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

Role: collaborator

NCT01047644Phase 2Completed

Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.

Role: collaborator

NCT01500876Not ApplicableUnknown

A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer

Role: collaborator

NCT02123030Completed

A Micro/Nano Device for Exhaled Breath Analysis

Role: collaborator

NCT00290459Completed

Prognostic Markers of Gynecologic Cancers

Role: collaborator

NCT00266279Phase 2Completed

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

Role: collaborator

NCT01772719Not ApplicableTerminated

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Role: collaborator